Denali Therapeutics Inc. (DNLI)
NASDAQ: DNLI · Real-Time Price · USD
19.21
-0.59 (-2.98%)
May 14, 2026, 1:51 PM EDT - Market open
Denali Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
507
Market Cap
3.05B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 330.53M | 222.07M | 204.74% |
| Dec 31, 2022 | 108.46M | 59.80M | 122.90% |
| Dec 31, 2021 | 48.66M | -287.00M | -85.50% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Tarsus Pharmaceuticals | 535.08M |
| Arcutis Biotherapeutics | 415.62M |
| Soleno Therapeutics | 285.01M |
| Arcus Biosciences | 236.00M |
| Beam Therapeutics | 164.01M |
| Tango Therapeutics | 56.99M |
| Alumis | 24.05M |
DNLI News
- 1 hour ago - Denali Therapeutics price target lowered to $40 from $42 at Morgan Stanley - TheFly
- 1 day ago - Denali Therapeutics Transcript: Bank of America Global Healthcare Conference 2026 - Transcripts
- 6 days ago - Denali Therapeutics price target lowered to $23 from $25 at Wedbush - TheFly
- 6 days ago - Denali Therapeutics Reports First Quarter 2026 Financial Results and Business Highlights - GlobeNewsWire
- 5 weeks ago - Denali Therapeutics price target raised to $34 from $32 at Baird - TheFly
- 5 weeks ago - Denali Therapeutics price target raised to $39 from $38 at BTIG - TheFly
- 5 weeks ago - Denali Therapeutics regains full rights to DNL593 - TheFly
- 5 weeks ago - Denali Therapeutics Regains Full Rights to Investigational Therapy DNL593 (PTV:PGRN) for GRN-related Frontotemporal Dementia (FTD-GRN) - GlobeNewsWire